Abstract. Famitinib (SHR1020), a novel multi-targeted tyrosine kinase inhibitor, has antitumor activity against several solid tumors via targeting vascular endothelial growth factor receptor 2, c-Kit and platelet-derived growth factor receptor β. The present study investigated famitinib's activity against human gastric cancer cells in vitro and in vivo. Cell viability and apoptosis were measured, and cell cycle analysis was performed following famitinib treatment using 3-(4,5-dimethylthiazol -2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl )-2H-tetrazolium assay, flow cytometry, terminal deoxynucleotidyl transferase dUTP nick end labeling assay and western blotting. Subsequently, cluster of differentiation 34 staining was used to evaluate microvessel density. BGC-823-derived xenografts in nude mice were established to assess drug efficacy in vivo. Famitinib inhibited cell proliferation by inducing cell cycle arrest at the G2/M phase and caused cell apoptosis in a dose-dependent manner in gastric cancer cell lines. In BGC-823 xenograft models, famitinib significantly slowed tumor growth in vivo via inhibition of angiogenesis. Compared with other chemotherapeutics such as 5-fluorouracil, cisplatin or paclitaxel alone, famitinib exhibited the greatest tumor suppression effect (>85% inhibition). The present study demonstrated for the first time that famitinib has efficacy against human gastric cancer in vitro and in vivo, which may lay the foundations for future clinical trials.
Introduction
In China, >60% of gastric cancer patients are initially diagnosed with locally advanced (or metastatic) gastric cancer (AGC) (1) , and fluorouracil-based combination chemotherapy is considered a first-line treatment (2) . However, clinical outcomes for AGC patients are unsatisfactory, with treatment offering modest responses and poor prognoses (3) . Trastuzumab added to this therapy has been documented to prolong the survival of human epidermal growth factor receptor 2 (HER2)-positive AGC patients, but HER2 expression is only reported to occur in 15-20% of all gastric cancers (4) . Thus, novel gastric cancer therapies are required.
In the past, tyrosine kinase inhibitors (TKIs), including imatinib (5), gefitinib (6) and erlotinib (7) , have been successfully used to treat other tumors (8) , but these drugs have not been used for gastric cancer, despite animal data suggesting their potential efficacy (9) . Famitinib (SHR1020) is a novel multi-targeted receptor TKI that targets vascular endothelial growth factor receptor 2 (VEGFR2), c-Kit and platelet-derived growth factor receptor β, and is inhibitory at 4.7±2.9, 2.3±2.6 and 6.6±1.1 nM, respectively (10) . Famitinib is a structural analog of sunitinib with improved cell inhibitory activity (Xie et al, unpublished data) . Due to its anti-angiogenic effect, famitinib was effective against metastatic renal cell carcinoma and metastatic breast cancer (11) (12) (13) (14) . Clinical trials of famitinib against other solid tumors such as advanced colorectal cancer and gastroenteropancreatic neuroendocrine tumors are underway (https://clinicaltrials.gov/). The present study demonstrates the potential antitumor activity of famitinib against human gastric cancer cells in vitro and in vivo.
Materials and methods
Drugs. Famitinib (SHR1020) was a gift from Jiangsu Hengrui Medicine Co., Ltd. (Lianyungang, China), and its appearance was a yellow powder. The drug was stored at 4˚C in the dark. For in vitro studies, famitinib was dissolved in dimethylsulfoxide at 20 mmol/l and stored at -20˚C until use. For in vivo animal experiments, famitinib was formulated in physiological saline as a homogeneous suspension (10 mg/ml) and stored at 4˚C protected from light. Injectable 5-florouracil (5-FU, 250 mg/10 ml) was purchased from Tianjin Jinyao Amino Cell cycle analysis. Cell were treated with famitinib for 48 h, followed by harvesting and fixing in 70% cold ethanol for ≥12 h at 4˚C. Cells were stained with 50 µg/ml propidium iodide (BD Biosciences, Franklin Lakes, NJ, USA) at room temperature for 30 min in the dark, and the cell cycle was analyzed using a FACSAria or a FACSCalibur (BD Biosciences). Data were analyzed by ModFit 3.0 software (BD Biosciences). All experiments were performed in triplicate.
Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay. Cell apoptosis was measured via TUNEL assay (catalog no., C1086; Beyotime Institute of Biotechnology, Haimen, China) according to the manufacturer's protocol. Upon treatment of the cells with famitinib for 48 h, cells were washed with phosphate-buffered saline (PBS) and fixed with 4% paraformaldehyde for 10 min at room temperature. Cells were then stained with the corresponding reagents provided in the TUNEL assay kit. Upon overlaying the coverslips, slides were imaged under fluorescence microscopy (TCS SP5; Leica Microsystems GmbH, Wetzlar, Germany). Positive cells exhibited green fluorescence and were counted from three random microscopic fields.
Western blotting. Total proteins prior and subsequent to famitinib treatment were extracted from BGC-823 and MGC-803 cell pellets using CytoBuster Protein Extraction Reagent (Merck Millipore, Darmstadt, Germany). Proteins were quantified with a Pierce BCA Protein Assay kit (Thermo Fisher Scientific, Inc.), and ~20 µg of protein was separated on 15% sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and proteins were then transferred to a nitrocellulose membrane (GE Healthcare Life Sciences, Chalfont, UK), which was subsequently incubated with anti-cyclin B1 (dilution, 1:1,000; catalog no., AJ1208a; Abgent Inc., San Diego, CA, USA), rabbit polyclonal anti-B-cell lymphoma 2 (BCL2; dilution, 1:1,000; catalog no., 2872; Cell Signaling Technology, Inc., Danvers, MA, USA) and mouse monoclonal anti-β-actin (dilution, 1:3,000; catalog no., A5441; Sigma-Aldrich, St. Louis, MO, USA) antibodies at 4˚C overnight. Secondary anti-rabbit and anti-mouse horseradish peroxidase-conjugated IgG antibodies (dilution, 1:3,000; catalog nos., 7074 and 7076, respectively; Cell Signaling Technology, Inc.) were applied and allowed to incubate at room temperature for 1 h. Proteins were visualized with ECL Plus Western Blotting Detection Reagent (GE Healthcare Life Sciences).
In vivo xenograft model experiments. BGC-823 cells were suspended in PBS (1x10 7 cells/ml), and 100 µl of the cell suspension was subcutaneously injected into the right axillary area of 18-20-g female BALB/c athymic nu/nu mice (n=40; age, 6-8 weeks; Vital River Laboratories Co., Ltd., Beijing, China). The temperature of the housing conditions was maintained at 23-25˚C with a humidity of 50-60% and a 10/14 h light/dark cycle. Food and water were changed 3 times a week. When the tumor volume reached ~100 mm 3 , mice were randomized into treatment groups. Tumors and animal weights were measured twice weekly, and tumor volume was calculated using the following formula: V=LxW 2 x1/2 (where V represents tumor volume, L is the length of the tumor and W is the width of the tumor).
To measure famitinib, three groups were randomized (n=5 mice/group) as follows: Control group (gavage, physiological saline, once daily for 3 weeks); low-dose famitinib group (gavage, 50 mg/kg, once daily for 3 weeks); and high-dose famitinib group (gavage, 100 mg/kg, once for 3 weeks). A dose of 50 mg/kg was used for the following experiments.
To compare famitinib with other drugs, animals were randomized (n=5 mice/group) as follows: Control group (gavage, physiological saline, once daily for 3 weeks); famitinib group (gavage, 50 mg/kg, once daily for 3 weeks); 5-FU group [10 mg/kg, intraperitoneal (ip), once every 2 days for 3 weeks]; DDP group (3 mg/kg, ip, once weekly for 3 weeks); and PTX group (10 mg/kg, ip, once a week for 3 weeks). Then, tumors and weight were quantified. All animal experiments were approved by the Institutional Ethics and Animal Care Committee and performed in accordance with the animal experimental guidelines of Peking University Cancer Hospital (Beijing, China).
Hematoxylin and eosin (H&E) and immunohistochemical staining.
Once the mice were sacrificed, xenografts were isolated, and formalin-fixed, paraffin-embedded (FFPE) tissue blocks were obtained. FFPE tumor sections (4-µm thick) were deparaffinized in xylene and hydrated in graded alcohol. Then, tumor sections were either stained using a H&E staining kit (catalog no., C0105; Beyotime Institute of Biotechnology), according to the manufacturer's protocol, or incubated with rabbit polyclonal anti-cluster of differentiation (CD)34 antibody (dilution, 1:2,500; catalog no., ab81289; Abcam, Cambridge, UK) upon antigen retrieval and endogenous peroxidase treatment. Signals were visualized using an immunoglobulin G-horseradish peroxidase polymer (Beijing CoWin Biotech Co., Ltd., Beijing, China) and 3,3'-diaminobenzidine substrate. Sections were scored by two independent pathologists as previously described (15) .
Statistical analysis. SPSS 18.0 software (SPSS, Inc., Chicago, IL, USA) was used to perform the statistical analysis. One-way analysis of variance was used for the in vivo experiments. P<0.05 was considered to indicate a statistically significant difference.
Results

Famitinib inhibits gastric cancer cell growth in a dose-dependent manner.
BGC-823 and MGC-803 cells were treated with famitinib (0, 0.6, 1.25, 2.5, 5.0, 10.0 and 20.0 µM) for 24, 48 and 72 h, followed by MTS assay. Famitinib inhibited cell growth in a dose-dependent manner (Fig. 1) . The half maximal inhibitory concentration (IC 50 ) values of famitinib in BGC-823 and MGC-803 cells were 3.6 and 3.1 µM, respectively. Based on these results, the IC 50 and 1/2 IC 50 were used for in vitro experiments.
Famitinib induces cell cycle arrest at the G2/M phase.
The cell cycle was next analyzed following famitinib treatment, and it was observed that the number of G2/M-phase cells increased in BGC-823 (27.98 vs. 14.25%) and MGC-803 (58.23 vs. 10.72%) cells compared with the control (P=0.04 and P=0.02, respectively; Fig. 2A and B) . Cell cycle arrest at the G2/M phase was confirmed by increased expression of the cell metaphase-specific protein cyclin B1 (Fig. 2C) .
Famitinib triggers apoptosis.
Cell apoptosis is an important mechanism of cell growth inhibition (16); therefore, apoptosis was measured via TUNEL assay. Fig. 3 indicates that, compared with the control, famitinib increased apoptosis in BGC-823 and MGC-803 cell lines significantly (P<0.01), and downregulated BCL2.
Famitinib reduces xenograft growth in vivo via inhibition of angiogenesis.
To identify the optimal famitinib dose for the in vivo study, two doses were used, 50 and 100 mg/kg. Both doses exerted a similar inhibitory power, but greater toxicity was observed with the highest dose (data not shown).
Mice were sacrificed 21 days after treatment, and tumors were isolated. Famitinib inhibited BGC-823 xenograft growth (tumor volume, 395.2 vs. 2,690.5 mm 3 , P<0.01; Fig. 4A ), and animal weights were similar between groups (21.6 vs. 18.7 g, P=0.17; Fig. 4B ).
Famitinib is considered to inhibit angiogenesis; therefore, microvessel density was measured with CD34 staining. Upon famitinib treatment, xenografts had greater tissue necrosis (Fig. 4C ) and exhibited significantly weaker CD34 staining than the controls (Fig. 4D) . Thus, famitinib inhibits tumor vascularization.
Famitinib has greater tumor inhibitory effect than 5-FU, DDP or PTX.
In clinical practice, 5-FU, DDP and PTX are the most commonly used chemotherapeutic drugs for gastric cancer. Thus, the activity of famitinib alone was compared with that of these compounds, and it was observed that famitinib exerted better tumor inhibition than 5-FU, DDP and PTX ( Fig. 4E and F) . The mean tumor volumes of the control, 5-FU, DDP, PTX and famitinib groups were 1,973.0, 1,680.3, 987.3, 1,577.6 and 287.6 mm 3 , respectively; and the corresponding tumor inhibitory ratios were 0.0, 14.9, 49.9, 20.0 and 85.4%, respectively.
Discussion
According to the data from phase I studies of famitinib against advanced solid tumors (11), one third of patients with AGC responded to famitinib and had a stabilized disease without further evaluation. Thus, the present data offer additional evidence for future trials of famitinib against gastric cancer. The current study confirmed that famitinib alone inhibited the growth of BGC-823 and MGC-803 gastric cancer cells in a dose-dependent manner in vitro (Fig. 1) . From the in vivo results, it was concluded that the inhibitory effect of famitinib in mice xenografts was greater than that of 5-FU, DDP or PTX alone (Fig. 4E and F) . Thus, famitinib has promising antitumor activity against gastric cancer. For 
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A animal experiments, 5-FU, DDP and PTX alone were dosed at 10, 3 and 10 mg/kg, respectively. According to our previous study (15) and the results from the present study (data not shown), although high doses of 5-FU, DDP and PTX (20, 6 and 20 mg/kg, respectively) alone had better antitumor activity than low doses of the same drugs, these were all toxic at higher doses. Furthermore, based on our preliminary results, the antitumor activity of famitinib was greater than high doses of 5-FU, DDP and PTX.
Combination regimens of ≥2 drugs for gastric cancer are commonly used in clinical practice (2) . In the present study, famitinib was not used with other drugs due to its impressive inhibitory activity (>85%). Thus, we anticipate that patients who do not have success with traditional treatment may be treated with famitinib for AGC and advanced colorectal cancer (NCT01762293; clinicaltrials.gov/ct2/show/NCT0176229).
The present study revealed that famitinib induced cell cycle arrest at the G2/M phase, which was validated by the upregulation of cyclin B1 (Fig. 2C) . In addition, cell apoptosis was triggered by famitinib, according to the results of TUNEL assay, and this was confirmed by the downregulation of BCL2 (Fig. 3) . Anti-angiogenesis was reported to be an important mechanism of famitinib (13), which was confirmed by the present study. Upon famitinib treatment, tumor microvessel density represented by CD34 staining was significantly lower than that exhibited by the controls (Fig. 4D) . Famitinib may have other targets, which may be studied in future experiments.
Anti-angiogenic therapy has been used since it was first proposed by Dr Judah Folkman in 1971 (17) . Although the frequent failures of anti-angiogenic drugs such as bevacizumab and sorafenib have been documented in the treatment of gastric cancer (18) (19) (20) , ramucirumab and apatinib, which mainly block VEGFR2, do improve the survival of patients with chemotherapy-refractory AGC compared with placebo (21) (22) (23) . Similar to ramucirumab and apatinib, famitinib mainly targets VEGFR2, which was not investigated in the present study. However, tumor microvessel density decreased upon famitinib treatment compared with the controls (Fig. 4D) . 
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In additional studies, we will futher validate the inhibitory effect of famitinib in gastric cancer patient-derived xenografts, as well as the synergistic effects of famitinib combined with common chemotherapeutic drugs. In conclusion, the present study demonstrated that famitinib induces cell cycle arrest at the G2/M phase and causes cell apoptosis and anti-angiogenesis. The present data can be used as a foundation for future studies to identify drugs to treat gastric cancer.
